Table 1. Patient characteristics.
| Variables* | All patients (N = 116) |
Chronic HCV infection (N = 92) |
p value | |||
|---|---|---|---|---|---|---|
| Acute HCV infection (N = 24) | Chronic HCV infection (N = 92) | p value | Genotype 1/6 (n = 53) | Genotype 2/3 (n = 39) | ||
| Mean age (SD), y | 35 (8) | 38 (8) | 0.15 | 38 (8) | 37 (8) | 0.48 |
| Sex | 0.99 | 0.99 | ||||
| Male | 22 (92) | 84 (91) | 48 (91) | 36 (92) | ||
| Female | 2 (8) | 8 (9) | 5 (9) | 3 (8) | ||
| Mean hemoglobin level (SD), g/dL | 15.6 (1.3) | 15.1 (1.3) | 0.18 | 14.8 (1.3) | 15.4 (1.2) | 0.12 |
| Mean white blood cell count (SD), 106 cells/L | 5,555 (1,456) | 6,064 (1,732) | 0.19 | 6,148 (1,748) | 5,951 (1,728) | 0.59 |
| Mean platelet count (SD), 109 cells/L | 239 (63) | 210 (68) | 0.06 | 211 (64) | 208 (74) | 0.83 |
| Mean albumin level (SD), g/L | 4.7 (0.2) | 4.6 (0.4) | 0.60 | 4.5 (0.4) | 4.6 (0.4) | 0.30 |
| Mean total bilirubin level (SD), mg/dL | 1.2 (0.6) | 1.2 (0.9) | 0.88 | 1.1 (0.8) | 1.2 (1.0) | 0.47 |
| Mean ALT quotient (SD) | 7.3 (6.7) | 3.3 (3.2) | <0.001 | 3.2 (3.0) | 3.4 (3.1) | 0.27 |
| HIV risk behavior | 0.06 | 0.03 | ||||
| IDU | 2 (8) | 27 (29) | 20 (38) | 7 (18) | ||
| MSM | 22 (92) | 62 (67) | 30 (57) | 32 (82) | ||
| Hemophilia | 0 (0) | 3 (3) | 3 (6) | 0 (0) | ||
| On HAART | 23 (96) | 83 (90) | 0.69 | 49 (92) | 34 (87) | 0.49 |
| Mean HIV RNA (SD), copies/mL | 5,550 (26,934) | 3,972 (15,294) | 0.71 | 3,976 (15,137) | 3,967 (15,704) | 0.99 |
| HIV-RNA <50 copies/mL | 18 (75) | 58 (63) | 0.34 | 34 (64) | 24 (62) | 0.83 |
| Mean CD4 cell count (SD), 106 cells/L | 439 (92) | 428 (85) | 0.21 | 415 (72) | 445 (99) | 0.10 |
| HCV RNA (SD), log10 IU/mL | 5.00 (1.45) | 6.16 (1.36) | <0.001 | 6.36 (1.16) | 5.90 (1.60) | 0.11 |
| HCV RNA ≥800,000 IU/mL | 8 (33) | 64 (70) | 0.002 | 38 (72) | 26 (67) | 0.65 |
| HCV genotype | 0.61 | <0.001 | ||||
| 1 | 10 (42) | 37 (40) | 37 (70) | 0 (0) | ||
| 1a | 1 (4) | 9 (10) | 9 (17) | 0 (0) | ||
| 1b | 9 (38) | 28 (30) | 28 (53) | 0 (0) | ||
| 2 | 12 (50) | 34 (37) | 0 (0) | 34 (87) | ||
| 2a | 12 (50) | 30 (33) | 0 (0) | 30 (77) | ||
| 2b | 0 (0) | 4 (4) | 0 (0) | 4 (10) | ||
| 3a | 0 (0) | 4 (4) | 0 (0) | 4 (10) | ||
| 6a | 1 (4) | 8 (9) | 8 (15) | 0 (0) | ||
| Mixed† | 1 (4) | 9 (10) | 8 (15) | 1 (3) | ||
| 1a + 1b | 1 (4) | 2 (2) | 2 (4) | 0 (0) | ||
| 1 + 2 | 0 (0) | 4 (4) | 4 (8) | 0 (0) | ||
| 1 + 6a | 0 (0) | 2 (2) | 2 (4) | 0 (0) | ||
| 2 + 3a | 0 (0) | 1 (1) | 0 (0) | 1 (3) | ||
| IL28B rs8099917 genotype | 0.80 | 0.45 | ||||
| TT | 19 (79) | 67 (73) | 36 (68) | 31 (79) | ||
| GT | 4 (17) | 21 (23) | 14 (26) | 7 (18) | ||
| GG | 1 (4) | 4 (4) | 3 (6) | 1 (3) | ||
| METAVIR fibrosis stage‡ | 0.005 | 0.47 | ||||
| F0 | 15 (63) | 22 (24) | 11 (21) | 11 (28) | ||
| F1 | 6 (25) | 26 (28) | 15 (28) | 11 (28) | ||
| F2 | 2 (8) | 22 (24) | 15 (28) | 7 (18) | ||
| F3 | 1 (4) | 13 (14) | 9 (17) | 4 (10) | ||
| F4 | 0 (0) | 8 (9) | 3 (6) | 5 (13) | ||
| Undetermined | 0 (0) | 1 (1) | 0 (0) | 1 (3) | ||
SD, standard deviation; ALT, alanine aminotransferase; HIV, human immunodeficiency virus; IDU, injection drug user; MSM, men who have sex with men; HAART, highly active antiretroviral therapy; CD, cluster of differentiation; RNA, ribonucleic acid; HCV, hepatitis C virus; IL28B, interleukin-28B.
*Values are numbers (percentages) unless otherwise indicated.
†Patients with mixed genotypes 1/2, or 1/6a infections were treated by the same protocol as those with genotype 1/6 monoinfection.
‡The stage of fibrosis was assessed by transient elastography (Fibroscan®, Echosens, Paris), and was determined according to the cut-off values proposed by Castera, et al49.